Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies.

Front Endocrinol (Lausanne) · 2026 · PMC13333457 · PMID 42440541

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Discontinuation due to AEs: Anlotinib exhibited the highest risk of discontinuation, with a risk 12 times that of placebo—a result that was highly significant.

also in 132,142 other papers

did not reach statistical significanceno p-value reported

However, the data show that although the incidence of ≥Grade 3 AEs in the selpercatinib group was numerically slightly higher than in the placebo group (OR = 1.34), the difference did not reach statistical significance and was notably lower than that observed in the MKIs group.

also in 111,027 other papers

showed a trendno p-value reported

In terms of PFS, all drugs showed a trend toward superiority over placebo, though to varying degrees.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.